Literature DB >> 22282663

Ovarian cancer risk associated with inherited inflammation-related variants.

Kristin L White1, Joellen M Schildkraut, Rachel T Palmieri, Edwin S Iversen, Andrew Berchuck, Robert A Vierkant, David N Rider, Bridget Charbonneau, Mine S Cicek, Rebecca Sutphen, Michael J Birrer, Paul P D Pharoah, Honglin Song, Jonathan Tyrer, Simon A Gayther, Susan J Ramus, Nicolas Wentzensen, Hannah P Yang, Montserrat Garcia-Closas, Catherine M Phelan, Julie M Cunningham, Brooke L Fridley, Thomas A Sellers, Ellen L Goode.   

Abstract

The importance of inflammation pathways to the development of many human cancers prompted us to examine the associations between single-nucleotide polymorphisms (SNP) in inflammation-related genes and risk of ovarian cancer. In a multisite case-control study, we genotyped SNPs in a large panel of inflammatory genes in 930 epithelial ovarian cancer cases and 1,037 controls using a custom array and analyzed by logistic regression. SNPs with P < 0.10 were evaluated among 3,143 cases and 2,102 controls from the Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) post-GWAS collaboration. Combined analysis revealed association with SNPs rs17561 and rs4848300 in the interleukin gene IL1A which varied by histologic subtype (P(heterogeneity) = 0.03). For example, IL1A rs17561, which correlates with numerous inflammatory phenotypes, was associated with decreased risk of clear cell, mucinous, and endometrioid subtype, but not with the most common serous subtype. Genotype at rs1864414 in the arachidonate 5-lipoxygenase ALOX5 was also associated with decreased risk. Thus, inherited variation in IL1A and ALOX5 seems to affect ovarian cancer risk which, for IL1A, is limited to rarer subtypes. Given the importance of inflammation in tumorigenesis and growing evidence of subtype-specific features in ovarian cancer, functional investigations will be important to help clarify the importance of inherited variation related to inflammation in ovarian carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22282663      PMCID: PMC3293997          DOI: 10.1158/0008-5472.CAN-11-3512

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Applications of computational algorithm tools to identify functional SNPs in cytokine genes.

Authors:  Jie Shen; Prescott L Deininger; Hua Zhao
Journal:  Cytokine       Date:  2006-08-17       Impact factor: 3.861

2.  Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. Radiologic Technologists.

Authors:  Alice J Sigurdson; Parveen Bhatti; Michele M Doody; Michael Hauptmann; Laura Bowen; Steven L Simon; Robert M Weinstock; Martha S Linet; Marvin Rosenstein; Marilyn Stovall; Bruce H Alexander; Dale L Preston; Jeffrey P Struewing; Preetha Rajaraman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-10       Impact factor: 4.254

3.  Polymorphisms of the interleukin-1 gene cluster and ovarian cancer.

Authors:  Lukas A Hefler; Elisabeth Ludwig; Antje Lebrecht; Robert Zeillinger; Dan Tong-Cacsire; Heinz Koelbl; Sepp Leodolter; Clemens B Tempfer
Journal:  J Soc Gynecol Investig       Date:  2002 Nov-Dec

4.  Lipoxygenase pathway receptor expression in ovarian cancer.

Authors:  Rodney P Rocconi; Tyler O Kirby; Robert S Seitz; Rod Beck; J Michael Straughn; Ronald D Alvarez; Warner K Huh
Journal:  Reprod Sci       Date:  2008-04       Impact factor: 3.060

5.  Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis.

Authors:  A-M Sims; A E Timms; J Bruges-Armas; R Burgos-Vargas; C-T Chou; T Doan; A Dowling; R N Fialho; P Gergely; D D Gladman; R Inman; M Kauppi; K Kaarela; K Laiho; W Maksymowych; J J Pointon; P Rahman; J D Reveille; R Sorrentino; J Tuomilehto; G Vargas-Alarcon; B P Wordsworth; H Xu; M A Brown
Journal:  Ann Rheum Dis       Date:  2007-12-06       Impact factor: 19.103

6.  Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.

Authors:  Susan J Ramus; Patricia A Harrington; Carole Pye; Richard A DiCioccio; Mark J Cox; Kim Garlinghouse-Jones; Ingrid Oakley-Girvan; Ian J Jacobs; Richard M Hardy; Alice S Whittemore; Bruce A J Ponder; M Steven Piver; Paul D P Pharoah; Simon A Gayther
Journal:  Hum Mutat       Date:  2007-12       Impact factor: 4.878

Review 7.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

8.  Inherited determinants of ovarian cancer survival.

Authors:  Ellen L Goode; Matthew J Maurer; Thomas A Sellers; Catherine M Phelan; Kimberly R Kalli; Brooke L Fridley; Robert A Vierkant; Sebastian M Armasu; Kristin L White; Gary L Keeney; William A Cliby; David N Rider; Linda E Kelemen; Monica B Jones; Prema P Peethambaram; Johnathan M Lancaster; Janet E Olson; Joellen M Schildkraut; Julie M Cunningham; Lynn C Hartmann
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

9.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

10.  Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.

Authors:  Kristin L White; Robert A Vierkant; Catherine M Phelan; Brooke L Fridley; Stephanie Anderson; Keith L Knutson; Joellen M Schildkraut; Julie M Cunningham; Linda E Kelemen; V Shane Pankratz; David N Rider; Mark Liebow; Lynn C Hartmann; Thomas A Sellers; Ellen L Goode
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

View more
  21 in total

1.  Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.

Authors:  Rayjean J Hung; Cornelia M Ulrich; Ellen L Goode; Yonathan Brhane; Kenneth Muir; Andrew T Chan; Loic Le Marchand; Joellen Schildkraut; John S Witte; Rosalind Eeles; Paolo Boffetta; Margaret R Spitz; Julia G Poirier; David N Rider; Brooke L Fridley; Zhihua Chen; Christopher Haiman; Fredrick Schumacher; Douglas F Easton; Maria Teresa Landi; Paul Brennan; Richard Houlston; David C Christiani; John K Field; Heike Bickeböller; Angela Risch; Zsofia Kote-Jarai; Fredrik Wiklund; Henrik Grönberg; Stephen Chanock; Sonja I Berndt; Peter Kraft; Sara Lindström; Ali Amin Al Olama; Honglin Song; Catherine Phelan; Nicholas Wentzensen; Ulrike Peters; Martha L Slattery; Thomas A Sellers; Graham Casey; Stephen B Gruber; David J Hunter; Christopher I Amos; Brian Henderson
Journal:  J Natl Cancer Inst       Date:  2015-08-29       Impact factor: 13.506

Review 2.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

3.  Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.

Authors:  Jeff Hirst; Harsh B Pathak; Stephen Hyter; Ziyan Y Pessetto; Thuc Ly; Stefan Graw; Devin C Koestler; Adam J Krieg; Katherine F Roby; Andrew K Godwin
Journal:  Cancer Res       Date:  2018-06-11       Impact factor: 12.701

Review 4.  Approaches to integrating germline and tumor genomic data in cancer research.

Authors:  Heather Spencer Feigelson; Katrina A B Goddard; Celine Hollombe; Sharna R Tingle; Elizabeth M Gillanders; Leah E Mechanic; Stefanie A Nelson
Journal:  Carcinogenesis       Date:  2014-08-12       Impact factor: 4.944

5.  Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.

Authors:  Fei Guo; Liu Feng; Ji-Long Hu; Mei-Ling Wang; Peng Luo; Xiao-Ming Zhong; An-Mei Deng
Journal:  Tumour Biol       Date:  2014-10-01

6.  A functional variant at miRNA-122 binding site in IL-1α 3' UTR predicts risk and HPV-positive tumours of oropharyngeal cancer.

Authors:  Yang Zhang; Erich M Sturgis; Yan Sun; Chuanzheng Sun; Qingyi Wei; Zhigang Huang; Guojun Li
Journal:  Eur J Cancer       Date:  2015-05-14       Impact factor: 9.162

Review 7.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

8.  Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).

Authors:  Anne M Mills; Lauren C Peres; Alice Meiss; Kari L Ring; Susan C Modesitt; Sarah E Abbott; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Ann G Schwartz; Paul D Terry; Kristin Wallace; Joellen M Schildkraut
Journal:  Int J Gynecol Pathol       Date:  2019-03       Impact factor: 2.762

9.  VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer.

Authors:  Jianfei Huang; Jing Zhang; Hongxia Li; Zhaohui Lu; Weiwei Shan; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

10.  Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.

Authors:  Mine S Cicek; Devin C Koestler; Brooke L Fridley; Kimberly R Kalli; Sebastian M Armasu; Melissa C Larson; Chen Wang; Stacey J Winham; Robert A Vierkant; David N Rider; Matthew S Block; Brandy Klotzle; Gottfried Konecny; Boris J Winterhoff; Habib Hamidi; Viji Shridhar; Jian-Bing Fan; Daniel W Visscher; Janet E Olson; Lynn C Hartmann; Marina Bibikova; Jeremy Chien; Julie M Cunningham; Ellen L Goode
Journal:  Hum Mol Genet       Date:  2013-04-09       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.